Department of Surgery, Liver Transplantation Institute, Inonu University, 44315, Malatya, Turkey.
J Gastrointest Cancer. 2020 Dec;51(4):1118-1121. doi: 10.1007/s12029-020-00484-y.
Liver transplantation is a curative treatment option for hepatocellular carcinoma. In this review, we aimed to review liver transplantation criteria for hepatocellular carcinoma and patient survivals.
We reviewed literature in terms of liver transplant criteria for hepatocellular carcinoma. Patient eligibility criteria, post-transplant survivals, tumor recurrence and expansion of Milan criteria rates were analyzed.
The Milan criteria, after being published in 1996, have become for deceased donor liver transplantation in hepatocellular carcinoma worldwide. Later, many transplant centers published their own liver transplant criteria. Most of the criteria consisted of morphological tumor characteristics based on tumor size and number. The newest published one is Malatya criteria. The 5-year overall survival according the all of the criteria is greater than 50%. There were just one paper which compare criteria according to survival and Malatya criteria were the best amongst extended criteria with 5-year OS 79.7% in that study.
It is clear that morphological criteria consisting only of tumor size and number are insufficient in patient selection for liver transplantation and should thus be combined with biological, inflammatory, radiological, pathological and genetic markers that predict the biological behavior of the tumor. Efforts to find the best criteria are still ongoing and 5-year overall survival should be greater than 60%.
肝移植是治疗肝细胞癌的一种有治愈可能的治疗方法。在本综述中,我们旨在回顾肝细胞癌的肝移植标准和患者生存率。
我们回顾了关于肝细胞癌肝移植标准的文献。分析了患者入选标准、移植后生存率、肿瘤复发和米兰标准扩展率。
米兰标准于 1996 年发表后,成为全球肝细胞癌的尸体供肝移植标准。后来,许多移植中心公布了自己的肝移植标准。大多数标准基于肿瘤大小和数量等形态学肿瘤特征。最新公布的是马拉蒂亚标准。根据所有标准,5 年总生存率均大于 50%。只有一篇论文根据生存率对标准进行了比较,在该研究中,扩展标准中以马拉蒂亚标准的 5 年 OS 79.7%为最佳。
显然,仅由肿瘤大小和数量组成的形态学标准在患者选择肝移植时是不够的,因此应结合生物学、炎症、影像学、病理学和预测肿瘤生物学行为的遗传标志物。寻找最佳标准的努力仍在继续,5 年总生存率应大于 60%。